Logos Global Management LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Logos Global Management LP reported 63 stock positions worth $1.9 billion. Its top holding was Revolution Medicines (RVMD) at 10.0% of the portfolio, followed by Erasca (ERAS, 9.3%) and Ideaya Biosciences (IDYA, 5.9%). Compared with Q4 2025, it opened 12 new positions, sold out of 12, added to 23 and reduced 21. The biggest buy was Centessa Pharmaceuticals (CNTA, shares +963%) and the biggest sale an exit from Cidara Therapeutics (CDTX).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001792126
- Portfolio Value
- $1.9B (Q1 2026)
- SEC Filing
- 0001172661-26-002196 ↗ filed May 15, 2026
Holdings Value
Holdings 63 stocks · $1.9B
| RVMD Revolution Medicines Inc. | 10.02% | 2,000,000 | $194.5M | No change |
| ERAS Erasca Inc. | 9.29% | 11,150,000 | $180.4M | Reduce -14.2% |
| IDYA Ideaya Biosciences Inc. | 5.92% | 3,450,000 | $115.0M | Add +10.4% |
| PRAX Praxis Precision Medicines I | 4.73% | 285,000 | $91.8M | Reduce -24.0% |
| CNTA Centessa Pharmaceuticals Ltd. | 4.35% | 2,125,000 | $84.4M | Add +962.5% |
| TERN Terns Pharmaceuticals Inc. | 4.07% | 1,500,000 | $79.1M | Add +100.0% |
| ABVX Abivax SA-ADR | 3.87% | 675,000 | $75.2M | Add +68.8% |
| TNGX Tango Therapeutics Inc. | 3.23% | 3,000,000 | $62.8M | Reduce -28.6% |
| CYTK Cytokinetics Inc. | 2.97% | 875,000 | $57.7M | Add +191.7% |
| OLMA Olema Pharmaceuticals Inc. | 2.46% | 3,208,875 | $47.8M | No change |
| UTHR United Therapeutics Corp. | 2.44% | 80,000 | $47.4M | New |
| IMCR Immunocore Holdings PLC-ADR | 2.33% | 1,500,000 | $45.2M | Add +76.5% |
| MDGL Madrigal Pharmaceuticals Inc. | 2.29% | 85,000 | $44.5M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 2.02% | 450,000 | $39.1M | Add +136.8% |
| CGON CG Oncology Inc. | 2.00% | 575,000 | $38.9M | Add +187.5% |
| MAZE Maze Therapeutics Inc. | 1.90% | 1,235,000 | $36.9M | Add +30.0% |
| BIIB Biogen Inc. | 1.89% | 200,000 | $36.7M | No change |
| IRON Disc Medicine Inc. | 1.84% | 560,000 | $35.8M | Add +9.8% |
| DNTH Dianthus Therapeutics Inc. | 1.73% | 400,000 | $33.6M | Add +27.0% |
| OCUL Ocular Therapeutix Inc. | 1.68% | 3,850,000 | $32.6M | Add +10.0% |
| TYRA Tyra Biosciences Inc. | 1.68% | 850,000 | $32.6M | Add +304.8% |
| TRVI Trevi Therapeutics Inc. | 1.47% | 2,400,000 | $28.6M | Add +54.8% |
| MLTX Moonlake Immunotherapeutics | 1.44% | 1,500,000 | $28.0M | Reduce -14.3% |
| IMVT Immunovant Inc. | 1.38% | 1,075,000 | $26.7M | Reduce -21.8% |
| XENE Xenon Pharmaceuticals Inc. | 1.35% | 450,000 | $26.2M | New |
| RCUS Arcus Biosciences Inc. | 1.33% | 1,200,000 | $25.9M | New |
| DYN Dyne Therapeutics Inc. | 1.31% | 1,400,000 | $25.4M | Add +12.0% |
| GPCR Structure Therapeutics Inc. | 1.24% | 500,000 | $24.1M | Reduce -16.7% |
| LBRX LB Pharmaceuticals Inc. | 1.16% | 915,000 | $22.6M | Reduce -23.8% |
| ELVN Enliven Therapeutics Inc. | 1.09% | 540,000 | $21.2M | Add +58.8% |
| DSGN Design Therapeutics Inc. | 1.07% | 1,950,000 | $20.7M | Reduce -22.0% |
| NERV Minerva Neurosciences Inc. | 1.00% | 3,215,000 | $19.4M | Reduce -2.9% |
| NAMS Newamsterdam Pharma Co. NV | 0.99% | 600,000 | $19.2M | Add +33.3% |
| MIRM Mirum Pharmaceuticals Inc. | 0.95% | 200,000 | $18.5M | Reduce -11.1% |
| PCVX Vaxcyte Inc. | 0.90% | 300,000 | $17.4M | Reduce -53.9% |
| ACAD Acadia Pharmaceuticals Inc. | 0.86% | 750,000 | $16.7M | Reduce -11.8% |
| CMPX Compass Therapeutics Inc. | 0.86% | 3,150,000 | $16.7M | Add +173.9% |
| CLDX Celldex Therapeutics Inc. | 0.73% | 450,000 | $14.3M | Add +28.6% |
| JANX Janux Therapeutics Inc. | 0.72% | 1,000,000 | $13.9M | No change |
| VOR Vor Biopharma Inc. | 0.69% | 750,000 | $13.4M | Add +650.0% |
| ALKS Alkermes PLC | 0.64% | 350,000 | $12.4M | New |
| ORIC Oric Pharmaceuticals Inc. | 0.62% | 950,000 | $12.0M | Add +111.1% |
| IMMX Immix Biopharma Inc. | 0.57% | 1,225,000 | $11.2M | Add +22.5% |
| TENX Tenax Therapeutics Inc. | 0.51% | 625,000 | $10.0M | New |
| AMLX Amylyx Pharmaceuticals Inc. | 0.50% | 700,000 | $9.7M | Reduce -26.3% |
| CBIO Crescent Biopharma Inc. | 0.46% | 482,500 | $8.9M | Reduce -19.6% |
| SLNO Soleno Therapeutics Inc. | 0.43% | 250,000 | $8.4M | Reduce -16.7% |
| AVBP Arrivent Biopharma Inc. | 0.42% | 350,000 | $8.1M | New |
| RLAY Relay Therapeutics Inc. | 0.38% | 750,000 | $7.5M | New |
| CRVS Corvus Pharmaceuticals Inc. | 0.34% | 450,000 | $6.6M | Reduce -10.0% |
| MGTX Meiragtx Holdings PLC | 0.31% | 700,000 | $6.1M | New |
| JBIO Jade Biosciences Inc. | 0.29% | 400,000 | $5.6M | Add +1.3% |
| VSTM Verastem Inc. | 0.27% | 1,000,000 | $5.3M | Reduce -41.2% |
| AVTX Avalo Therapeutics Inc. | 0.23% | 300,000 | $4.5M | New |
| UNCY Unicycive Therapeutics Inc. | 0.16% | 473,563 | $3.1M | No change |
| IBIO Ibio Inc. | 0.13% | 1,300,000 | $2.5M | Reduce -35.0% |
| PTN Palatin Technologies Inc. | 0.13% | 140,000 | $2.4M | No change |
| ACRS Aclaris Therapeutics Inc. | 0.10% | 500,000 | $1.9M | Reduce -16.7% |
| PHVS Pharvaris NV | 0.09% | 65,000 | $1.8M | Reduce -35.0% |
| MANE Veradermics Inc. | 0.08% | 25,000 | $1.6M | New |
| FTH Faeth Therapeutics Inc. filed as SENSEI BIOTHERAPEUTICS INC | 0.05% | 30,000 | $946K | New |
| SEPN Septerna Inc. | 0.03% | 23,548 | $566K | No change |
| GUTS Fractyl Health Inc. | 0.02% | 1,000,000 | $458K | Reduce -9.1% |
Options reported separately and not counted above: TERN calls ($26.4M), ELVN calls ($19.6M), AVTX calls ($14.9M).
Portfolio Sells Q4 2025 → Q1 2026
| CDTX Cidara Therapeutics Inc. | Sold out | 0.00% | −4.56 |
| PRAX Praxis Precision Medicines I | Reduce -24.0% | 4.73% | −2.64 |
| RNAM Avidity Biosciences Inc. | Sold out | 0.00% | −2.40 |
| JAZZ Jazz Pharmaceuticals PLC | Sold out | 0.00% | −2.27 |
| GPCR Structure Therapeutics Inc. | Reduce -16.7% | 1.24% | −1.54 |
| PCVX Vaxcyte Inc. | Reduce -53.9% | 0.90% | −1.10 |
| QURE Uniqure NV | Sold out | 0.00% | −1.08 |
| KNSA Kiniksa Pharmaceuticals Inte | Sold out | 0.00% | −0.96 |
| IMVT Immunovant Inc. | Reduce -21.8% | 1.38% | −0.95 |
| KYMR Kymera Therapeutics Inc. | Sold out | 0.00% | −0.67 |
| ACAD Acadia Pharmaceuticals Inc. | Reduce -11.8% | 0.86% | −0.65 |
| NRIX Nurix Therapeutics Inc. | Sold out | 0.00% | −0.63 |
| LBRX LB Pharmaceuticals Inc. | Reduce -23.8% | 1.16% | −0.62 |
| VSTM Verastem Inc. | Reduce -41.2% | 0.27% | −0.60 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −0.50 |
| SLNO Soleno Therapeutics Inc. | Reduce -16.7% | 0.43% | −0.49 |
| DSGN Design Therapeutics Inc. | Reduce -22.0% | 1.07% | −0.49 |
| NGNE Neurogene Inc. | Sold out | 0.00% | −0.27 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -26.3% | 0.50% | −0.26 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -11.1% | 0.95% | −0.23 |
| DAWN Day One Biopharmaceuticals I | Sold out | 0.00% | −0.19 |
| GUTS Fractyl Health Inc. | Reduce -9.1% | 0.02% | −0.14 |
| IBIO Ibio Inc. | Reduce -35.0% | 0.13% | −0.13 |
| MLTX Moonlake Immunotherapeutics | Reduce -14.3% | 1.44% | −0.10 |
| PHVS Pharvaris NV | Reduce -35.0% | 0.09% | −0.09 |
| MREO Mereo Biopharma Group PL-ADR | Sold out | 0.00% | −0.05 |
| DBVT DBV Technologies SA-Spon ADR | Sold out | 0.00% | −0.03 |
| ACRS Aclaris Therapeutics Inc. | Reduce -16.7% | 0.10% | −0.02 |
| CBIO Crescent Biopharma Inc. | Reduce -19.6% | 0.46% | −0.02 |
| CRVS Corvus Pharmaceuticals Inc. | Reduce -10.0% | 0.34% | +0.08 |
| NERV Minerva Neurosciences Inc. | Reduce -2.9% | 1.00% | +0.11 |
| TNGX Tango Therapeutics Inc. | Reduce -28.6% | 3.23% | +0.75 |
| ERAS Erasca Inc. | Reduce -14.2% | 9.29% | +6.07 |
Portfolio Buys Q4 2025 → Q1 2026
| CNTA Centessa Pharmaceuticals Ltd. | Add +962.5% | 4.35% | +4.01 |
| UTHR United Therapeutics Corp. | New | 2.44% | +2.44 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 2.29% | +2.29 |
| TERN Terns Pharmaceuticals Inc. | Add +100.0% | 4.07% | +2.05 |
| CYTK Cytokinetics Inc. | Add +191.7% | 2.97% | +1.70 |
| CGON CG Oncology Inc. | Add +187.5% | 2.00% | +1.45 |
| XENE Xenon Pharmaceuticals Inc. | New | 1.35% | +1.35 |
| RCUS Arcus Biosciences Inc. | New | 1.33% | +1.33 |
| TYRA Tyra Biosciences Inc. | Add +304.8% | 1.68% | +1.31 |
| DNTH Dianthus Therapeutics Inc. | Add +27.0% | 1.73% | +0.86 |
| ELVN Enliven Therapeutics Inc. | Add +58.8% | 1.09% | +0.74 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +136.8% | 2.02% | +0.66 |
| ALKS Alkermes PLC | New | 0.64% | +0.64 |
| VOR Vor Biopharma Inc. | Add +650.0% | 0.69% | +0.60 |
| TENX Tenax Therapeutics Inc. | New | 0.51% | +0.51 |
| CMPX Compass Therapeutics Inc. | Add +173.9% | 0.86% | +0.45 |
| AVBP Arrivent Biopharma Inc. | New | 0.42% | +0.42 |
| RLAY Relay Therapeutics Inc. | New | 0.38% | +0.38 |
| ORIC Oric Pharmaceuticals Inc. | Add +111.1% | 0.62% | +0.37 |
| IMCR Immunocore Holdings PLC-ADR | Add +76.5% | 2.33% | +0.36 |
| MGTX Meiragtx Holdings PLC | New | 0.31% | +0.31 |
| ABVX Abivax SA-ADR | Add +68.8% | 3.87% | +0.28 |
| AVTX Avalo Therapeutics Inc. | New | 0.23% | +0.23 |
| IMMX Immix Biopharma Inc. | Add +22.5% | 0.57% | +0.23 |
| TRVI Trevi Therapeutics Inc. | Add +54.8% | 1.47% | +0.18 |
| CLDX Celldex Therapeutics Inc. | Add +28.6% | 0.73% | +0.10 |
| MANE Veradermics Inc. | New | 0.08% | +0.08 |
| FTH Faeth Therapeutics Inc. | New | 0.05% | +0.05 |
| NAMS Newamsterdam Pharma Co. NV | Add +33.3% | 0.99% | −0.06 |
| JBIO Jade Biosciences Inc. | Add +1.3% | 0.29% | −0.12 |
| DYN Dyne Therapeutics Inc. | Add +12.0% | 1.31% | −0.32 |
| MAZE Maze Therapeutics Inc. | Add +30.0% | 1.90% | −0.72 |
| IRON Disc Medicine Inc. | Add +9.8% | 1.84% | −0.85 |
| OCUL Ocular Therapeutix Inc. | Add +10.0% | 1.68% | −1.15 |
| IDYA Ideaya Biosciences Inc. | Add +10.4% | 5.92% | −1.28 |
Options Activity Q4 2025 → Q1 2026
| RVMD Revolution Medicines Inc. | call | Sold out | 1,000,000 | $79.7Mbefore exit |
| TERN Terns Pharmaceuticals Inc. | call | New | 500,000 | $26.4M |
| APLS Apellis Pharmaceuticals Inc. | call | Sold out | 1,000,000 | $25.1Mbefore exit |
| RCUS Arcus Biosciences Inc. | call | Sold out | 1,050,000 | $25.0Mbefore exit |
| ELVN Enliven Therapeutics Inc. | call | New | 500,000 | $19.6M |
| IDYA Ideaya Biosciences Inc. | call | Sold out | 450,000 | $15.6Mbefore exit |
| AVTX Avalo Therapeutics Inc. | call | New | 1,000,000 | $14.9M |
| IMTX Immatics NV | call | Sold out | 850,000 | $8.9Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q4 2025 → Q1 2026
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | Sold out | 66,666 | $22Kbefore exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $2.3B | ERAS, ABVX, RVMD, IDYA, BNTX |
| Q1 2026 | 63 | $1.9B | RVMD, ERAS, IDYA, PRAX, CNTA |
| Q4 2025 | 63 | $1.5B | RVMD, PRAX, IDYA, OLMA, CDTX |
| Q3 2025 | 52 | $1.0B | RVMD, IDYA, AKRO, ARVN, OCUL |
| Q2 2025 | 44 | $748.6M | IDYA, AKRO, RVMD, JAZZ, IRON |
| Q1 2025 | 38 | $562.5M | IDYA, RVMD, AKRO, JANX, NUVL |
| Q4 2024 | 46 | $854.6M | IDYA, JANX, RVMD, CYTK, VERA |
| Q3 2024 | 53 | $892.7M | IDYA, GPCR, RVMD, IRON, JANX |
| Q2 2024Amended | 50 | $867.8M | IDYA, ARGX, MRUS, RVMD, GPCR |
| Q1 2024 | 49 | $950.2M | IDYA, IMCR, IMVT, OCUL, SRPT |